<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>UNLABELLED: The incidence of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (<z:chebi fb="49" ids="35181">ADC</z:chebi>) has been increasing rapidly over the past few decades </plain></SENT>
<SENT sid="1" pm="."><plain>Gastro-esopageal reflux disease (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>), <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (BE) and Barrett-associated <z:mpath ids='MPATH_589'>dysplasia</z:mpath> are a risk factor for <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e>, but endoscopic surveillance have only a limited influence on <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality </plain></SENT>
<SENT sid="2" pm="."><plain>There is a great need to find molecular biomarkers predicting increased progression risk in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>-Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath>-<z:mpath ids='MPATH_589'>dysplasia</z:mpath>-<z:mp ids='MP_0009308'>adenocarcinoma</z:mp> sequence to improve risk assessment and stratification of patients to surveillance program </plain></SENT>
<SENT sid="3" pm="."><plain>AIM OF THE STUDY: To evaluate the polymorphism and prevalence of loss of heterozygosity (LOH) of APC <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene in mataplasia, <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>MATERIAL AND METHODS: In esophageal mucosal samples of 79 patients with: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> (n=33), BE (n=27), BE+<z:mpath ids='MPATH_589'>dysplasia</z:mpath> (n=8) and <z:chebi fb="49" ids="35181">ADC</z:chebi> (n=11) we have studied LOH of APC <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene using PCR-restriction fragment length polymorphism (RFLP) </plain></SENT>
<SENT sid="5" pm="."><plain>A 133 bp fragment, spanning exon 11 of the APC gene was amplified, and Rsal digestion of the PCR product defined the alleles as either homozygous 133 bp (Rsa(-/-)) or 87 and 46 bp (Rsa(+/+)) fragments, and heterozygous (Rsa(+/-)) exhibiting the three fragments </plain></SENT>
<SENT sid="6" pm="."><plain>Control peripheral blood cell DNA samples have been collected from 60 <z:mpath ids='MPATH_458'>normal</z:mpath> healthy subjects </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Among 79 patients, there were 16 heterozygous (20%) for APC gene </plain></SENT>
<SENT sid="8" pm="."><plain>In 16 informative heterozygous LOH was detected in 7 cases: 2/5 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>, 3/7--with BE, 1/2--with BE+<z:mpath ids='MPATH_589'>dysplasia</z:mpath> and 1/2--with <z:chebi fb="49" ids="35181">ADC</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>There were no statistical differences between studied groups (NS) </plain></SENT>
<SENT sid="10" pm="."><plain>Distribution of the three alleles, Rsa(+/-), Rsa(+/+), and Rsa(-/-) was: 38, 47 and 15% in the healthy individuals, 25%, 25% and 50%--in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> patients, 29%, 41% and 29%--in BE, 36%, 45% and 18% in BE+<z:mpath ids='MPATH_589'>dysplasia</z:mpath> and 25%, 67% and 8% in <z:chebi fb="49" ids="35181">ADC</z:chebi> patients, respectively </plain></SENT>
<SENT sid="11" pm="."><plain>The frequency of heterozygous cases in control group was significantly higher than in patients group (p = 0.018), whereas Rsa (-/-) were the most frequent in patients group (p = 0.008) </plain></SENT>
<SENT sid="12" pm="."><plain>Rsa (-/-) were seen significantly more often in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> compared to <z:chebi fb="49" ids="35181">ADC</z:chebi> patients (p = 0.005), in opposite to Rsa (+/+), which were significantly more frequent in <z:chebi fb="49" ids="35181">ADC</z:chebi> vs. <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> (p = 0.007) </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: APC gene inactivation concerns minority of patients with esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, however, its detection indicates higher risk of progression to <z:chebi fb="49" ids="35181">ADC</z:chebi> </plain></SENT>
<SENT sid="14" pm="."><plain>APC alternations appear to be early in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>-BE-<z:mpath ids='MPATH_589'>dysplasia</z:mpath>-<z:chebi fb="49" ids="35181">ADC</z:chebi> sequence </plain></SENT>
<SENT sid="15" pm="."><plain>The specific polymorphism may identify patients with high risk of progression into BE </plain></SENT>
</text></document>